The estimated Net Worth of Rajesh C Md Shrotriya is at least $30.5 Milion dollars as of 17 May 2018. Rajesh Shrotriya owns over 362,926 units of CASI Pharmaceuticals Inc stock worth over $4,255,014 and over the last 21 years he sold CASI stock worth over $26,073,379. In addition, he makes $125,600 as Independent Director at CASI Pharmaceuticals Inc.
Sign up
Rajesh Shrotriya CASI stock SEC Form 4 insiders trading
Rajesh has made over 27 trades of the CASI Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 362,926 units of CASI stock worth $529,872 on 17 May 2018.
The largest trade he's ever made was exercising 5,199,584 units of CASI Pharmaceuticals Inc stock on 9 January 2018 worth over $39,516,838. On average, Rajesh trades about 88,166 units every 23 days since 2003. As of 17 May 2018 he still owns at least 563,578 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Rajesh Shrotriya stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rajesh Shrotriya biography
Dr. Rajesh C. Shrotriya M.D. serves as Independent Director of the Company. Dr. Shrotriya has been a director of the Company since September 2014. From 2000 – 2017, he was President and Chief Operating Officer and Chief Executive Officer of Spectrum Pharmaceuticals. In this capacity, he spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. He is also a Director of the UNVL Foundation. Prior to joining Spectrum, from September 2000 to August 2002, Dr. Shrotriya was President and COO of Neotherapeutics, Inc., and prior to that he was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.
What is the salary of Rajesh Shrotriya?
As the Independent Director of CASI Pharmaceuticals Inc, the total compensation of Rajesh Shrotriya at CASI Pharmaceuticals Inc is $125,600. There are 10 executives at CASI Pharmaceuticals Inc getting paid more, with Wei-Wu He having the highest compensation of $9,269,690.
How old is Rajesh Shrotriya?
Rajesh Shrotriya is 76, he's been the Independent Director of CASI Pharmaceuticals Inc since 2019. There are no older and 11 younger executives at CASI Pharmaceuticals Inc.
What's Rajesh Shrotriya's mailing address?
Rajesh's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DR. SUITE 300, ROCKVILLE, MD, 20850.
Insiders trading at CASI Pharmaceuticals Inc
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya a Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
What does CASI Pharmaceuticals Inc do?
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
What does CASI Pharmaceuticals Inc's logo look like?
Complete history of Rajesh Shrotriya stock trades at CASI Pharmaceuticals Inc a Spectrum Pharmaceuticals
CASI Pharmaceuticals Inc executives and stock owners
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Wei-Wu He,
Executive Chairman of the Board, Chief Executive Officer -
Alexander Zukiwski,
Chief Medical Officer -
Wei Zhang,
President, President of CASI China, Interim Principal Financial Officer -
Dr. Wei-Wu He Ph.D.,
Chairman & CEO -
Dr. Wei Zhang Ph.D.,
Pres & Principal Financial Officer -
Dr. Alexander A. Zukiwski M.D.,
Exec. VP & Chief Medical Officer -
James Huang,
Independent Director -
Y. Alexander Wu,
Independent Director -
Franklin Salisbury,
Independent Director -
Quan Zhou,
Independent Director -
Rajesh Shrotriya,
Independent Director -
Amanda Cui,
VP & Global Controller -
Dr. James E. Goldschmidt Ph.D.,
Chief Bus. Devel. Officer -
Sara B. Capitelli CPA,
VP of Fin. -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Ren,
CEO and Director -
Pharmaceuticals Inc Spectru...,
-
Alex Wu,
Director -
Tak W. Mak,
Director -
China Growth Fund Iii L.P.I...,
-
Strategy Holding Ltd Wealth,
10% owner -
Sara B Capitelli,
VP, Finance & PAO -
George Chi,
Chief Financial Officer -
Cynthia W. Hu,
See Remarks -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Keyong Ren,
Chief Executive Officer -
Larry Zhang,
President -
Weihao Xu,
Chief Financial Officer